Standout Papers

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes 2025 202616
  1. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (2025)
    Rajiv Agarwal, Jennifer B. Green et al. New England Journal of Medicine

Immediate Impact

1 from Science/Nature 59 standout
Sub-graph 1 of 22

Citing Papers

Chronic kidney disease
2025 Standout
Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies
2025 Standout
1 intermediate paper

Works of Markus F. Scheerer being referenced

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
2021
Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
2020

Author Peers

Author Last Decade Papers Cites
Markus F. Scheerer 494 278 187 36 671
J. L. Ruse 471 281 182 22 742
Aliza Rozenberg 637 262 200 26 719
Ilan Yanuv 637 261 200 25 718
Shigehiro Karashima 526 333 189 69 777
Conn Jw 328 200 136 28 602
Daniel Lorber 395 158 125 24 765
Hulda J. Wohltmann 397 211 148 30 755
Gary K. Yang 362 351 149 28 618
Cristián A. Amador 353 201 127 22 779
Lakshini Y. Herat 397 223 171 34 695

All Works

Loading papers...

Rankless by CCL
2026